Published 28th January 2016

Significant licence deal for Abzena

Portfolio company Abzena, a life sciences group providing services and technologies to enable development and manufacture of biopharmaceutical products, has signed a significant licensing deal for its novel site specific ThioBridge™ antibody drug conjugate (ADC) linker technology. The partner is a publicly listed US biotech company that is developing and commercialising oncology therapies, including ADCs.

Dr John Burt,CEO of Abzena commented:

“Signing a licence for ThioBridge™ with a large US biotech partner is a key milestone for us and a great endorsement of our proprietary technology and expertise.”

“Through the research collaboration, our scientists have built a strong working relationship with our partner and have demonstrated the value of the ThioBridge™ technology in creating novel ADCs. We look forward to continuing to work together as this ADC progresses to and through clinical development.”

Learn more about the deal in Abzena's website

Press contacts